Issue of Equity

RNS Number:3228O
Tepnel Life Sciences PLC
05 August 2003

FOR IMMEDIATE RELEASE
                                                                  05 August 2003


              Tepnel Life Sciences PLC ("Tepnel" or "the Company")

                                     Placing


Manchester, UK. 5 August 2003... Tepnel Life Sciences PLC (AIM: TED) is pleased
to announce that it has raised approximately #1.5 million (before expenses)
through the placing of 9,733,128 new ordinary shares of 1p each in the Company
("Ordinary Shares") at 16 pence per share with both existing and new
institutional shareholders. These funds will be used for the accelerated
development of the Nucleomax (T3000) DNA purification system, Tepnel's latest
automated system, which is being designed for the rapid purification of DNA from
blood samples for pharmacogenomic applications. In addition, the new funds will
be used to extend Tepnel's activities for its existing automated products, such
as the Nucleopure (T2000), and to facilitate the move from Tepnel Scientific
Services Limited's existing premises in Edinburgh Scotland to a new facility in
Livingston.

Application has been made for the admission of the 9,733,128 new Ordinary Shares
to trading on AIM.  The new Ordinary Shares will rank pari passu with the
existing Ordinary Shares of the Company and dealings are expected to commence on
Friday 8 August 2003.

Commenting on today's announcement, Ben Matzilevich, Tepnel's CEO, said: "We are
very pleased to have completed this placement raising #1.5 million with support
from both existing and new institutional shareholders. These funds, in
combination with our tight internal control on costs and increasing revenues
from existing automated systems, products and services, puts Tepnel in an
excellent position to further grow its business both organically and by
acquisition."

Seymour Pierce acted as Placement Agent for the fund raising.


Further enquiries:

Tepnel Life Sciences - 0161 946 2200
Ben Matzilevich, CEO
Gron Ffoulkes-Davies, Finance Director

Seymour Pierce - 0207 107 8000
Mark Percy, Corporate Finance

HCC De Facto Group - 020 7496 3300
David Dible / Mark Swallow


Notes to Editors

Tepnel Life Sciences is a global biotechnology company with a "tripolar"
strategy focused on providing the biomedical industry with high-throughput
automated DNA purification systems, manual DNA purification kits and reagents,
as well as scientific services for nucleic acid purification, drug analysis,
genotyping and genetically modified foods (GMOs).

The Company was founded in 1992 to exploit DNA technology generated at UMIST
(University of Manchester Institute of Science and Technology) and is listed on
the AIM segment of the London Stock Exchange (AIM: TED).



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
IOEKZLFBXVBFBBL